Advertisement Pharmaceutical Business review - Page 897 of 5277 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 12, 2026

FDA grants priority review for Roche’s Tecentriq combo sBLA

Roche has received the US Food and Drug Administration (FDA) priority review for its supplemental biologics licence application (sBLA) for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy for colon cancer.

The submission is supported by data from the Phase III ATOMIC study. Credit: Gorodenkoff / Shutterstock.com.